Jagsonpal Pharmaceuticals Share Price
Start SIP in Jagsonpal Pharmaceuticals
Start SIPJagsonpal Pharmaceuticals Performance
Day Range
- Low 405
- High 412
52 Week Range
- Low 274
- High 452
- Open Price411
- Previous Close410
- Volume29804
Jagsonpal Pharmaceuticals Investment Rating
-
Master Rating:
-
Jagsonpal Pharmaceuticals has an operating revenue of Rs. 209.99 Cr. on a trailing 12-month basis. An annual revenue de-growth of -10% needs improvement, Pre-tax margin of 14% is healthy, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 7% and 16% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 9% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 52 which is a POOR score indicating inconsistency in earnings, a RS Rating of 44 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 46 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 61 | 43 | 47 | 58 | 60 | 55 |
Operating Expenses Qtr Cr | 51 | 41 | 44 | 49 | 52 | 50 |
Operating Profit Qtr Cr | 10 | 3 | 3 | 8 | 9 | 5 |
Depreciation Qtr Cr | 1 | 0 | 0 | 0 | 0 | 0 |
Interest Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 |
Tax Qtr Cr | 2 | 1 | 1 | 2 | 3 | 2 |
Net Profit Qtr Cr | 5 | 4 | 4 | 7 | 7 | 6 |
Jagsonpal Pharmaceuticals Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 10
- Bearish Moving Average
- ___
- 6
- 20 Day
- ₹404.82
- 50 Day
- ₹386.55
- 100 Day
- ₹369.75
- 200 Day
- ₹362.12
- 20 Day
- ₹408.92
- 50 Day
- ₹383.30
- 100 Day
- ₹360.51
- 200 Day
- ₹352.05
Jagsonpal Pharmaceuticals Resistance and Support
Resistance | |
---|---|
First Resistance | 410.40 |
Second Resistance | 414.95 |
Third Resistance | 417.65 |
RSI | 52.86 |
MFI | 75.89 |
MACD Single Line | 10.61 |
MACD | 8.16 |
Support | |
---|---|
First Support | 403.15 |
Second Support | 400.45 |
Third Supoort | 395.90 |
Jagsonpal Pharmaceuticals Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 31,206 | 1,797,154 | 57.59 |
Week | 107,150 | 6,213,629 | 57.99 |
1 Month | 132,100 | 6,305,120 | 47.73 |
6 Month | 69,022 | 3,450,421 | 49.99 |
Jagsonpal Pharmaceuticals Result Highlights
Jagsonpal Pharmaceuticals Synopsis
NSE-Medical-Diversified
Jagsonpal Pharma is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 208.70 Cr. and Equity Capital is Rs. 13.22 Cr. for the Year ended 31/03/2024. Jagsonpal Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 17/08/1978 and has its registered office in the State of Delhi, India. Company’s Corporate Identification Number(CIN) is L74899DL1978PLC009181 and registration number is 009181.Market Cap | 1,085 |
Sales | 210 |
Shares in Float | 0.85 |
No of funds | 9 |
Yield | 1.22 |
Book Value | 5.79 |
U/D Vol ratio | 2.2 |
LTDebt / Equity | |
Alpha | -0.13 |
Beta | 1.18 |
Jagsonpal Pharmaceuticals Shareholding Pattern
Owner Name | Jun-24 | Mar-24 | Dec-23 | Sep-23 |
---|---|---|---|---|
Promoters | 68.04% | 68.09% | 68.48% | 68.71% |
Mutual Funds | ||||
Foreign Portfolio Investors | 1.1% | 0.73% | 0.53% | 0.38% |
Financial Institutions/ Banks | ||||
Individual Investors | 20.79% | 20.68% | 21.94% | 21.99% |
Others | 10.07% | 10.5% | 9.05% | 8.92% |
Jagsonpal Pharmaceuticals Management
Name | Designation |
---|---|
Mr. Rajpal Singh Kochhar | Chairman Emeritus |
Mr. Harsha Raghavan | Chairman & Non-Exe.Director |
Mr. Manish Gupta | Managing Director |
Mr. Prithipal Singh Kochhar | Non Executive Director |
Mr. Debasis Bikash Nandy | Independent Director |
Ms. Radhika Madhukar Dudhat | Independent Director |
Ms. Pallavi Dinodia Gupta | Independent Director |
Jagsonpal Pharmaceuticals Forecast
Price Estimates
Jagsonpal Pharmaceuticals Corporate Action
Date | Purpose | Remarks |
---|---|---|
2024-08-07 | Quarterly Results | |
2024-05-20 | Audited Results & Final Dividend | |
2024-02-02 | Quarterly Results | |
2023-11-03 | Quarterly Results | |
2023-08-02 | Quarterly Results |
Date | Purpose | Remarks |
---|---|---|
2024-09-06 | FINAL | Rs.5.00 per share(100%)Final Dividend |
2023-08-21 | FINAL | Rs.5.00 per share(100%)Dividend |
2021-11-01 | INTERIM | Rs.4.00 per share(80%)Interim Dividend |
Jagsonpal Pharmaceuticals FAQs
What is Share Price of Jagsonpal Pharmaceuticals ?
Jagsonpal Pharmaceuticals share price is ₹405 As on 18 September, 2024 | 21:20
What is the Market Cap of Jagsonpal Pharmaceuticals ?
The Market Cap of Jagsonpal Pharmaceuticals is ₹1073.8 Cr As on 18 September, 2024 | 21:20
What is the P/E ratio of Jagsonpal Pharmaceuticals ?
The P/E ratio of Jagsonpal Pharmaceuticals is 52.9 As on 18 September, 2024 | 21:20
What is the PB ratio of Jagsonpal Pharmaceuticals ?
The PB ratio of Jagsonpal Pharmaceuticals is 5.7 As on 18 September, 2024 | 21:20